Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
Clinical trial NCT06081062 · UNKNOWN
Trial details
- NCT number
- NCT06081062
- Sponsor
- ISU Abxis Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-14
- Primary completion
- 2025-06-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.